AstraZeneca sees profits surge despite Chinese import tax allegations
Profit after tax rose to $7 billion last year, up from $6 billion in 2023, the company said, noting a sharp increase in sales of cancer medicines.

Mar 15, 2025 0
Mar 15, 2025 0
Mar 15, 2025 0
Mar 15, 2025 0
Mar 15, 2025 0
Mar 15, 2025 0
Or register with email
Jan 27, 2025 0
Jan 28, 2025 0
Mar 1, 2025 0
Feb 24, 2025 0
Feb 24, 2025 0
Jan 30, 2025 1
Jan 29, 2025 0
Jan 28, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.